Experience of using Anifrolumab in the treatment of patients with systemic lupus erythematosus
The aim – evaluation of the efficacy and safety of anifrolumab (AFM) therapy in patients with severe and moderate systemic lupus erythematosus (SLE) in real clinical practice.Material and methods. A prospective observational study (6 months) involving 14 patients with SLE (13 women and 1 man; mean a...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA PRESS LLC
2025-03-01
|
| Series: | Научно-практическая ревматология |
| Subjects: | |
| Online Access: | https://rsp.mediar-press.net/rsp/article/view/3698 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849243251544948736 |
|---|---|
| author | E. V. Bolotova E. V. Jakovleva E. K. Ilinykh Т. A. Rassovskaya |
| author_facet | E. V. Bolotova E. V. Jakovleva E. K. Ilinykh Т. A. Rassovskaya |
| author_sort | E. V. Bolotova |
| collection | DOAJ |
| description | The aim – evaluation of the efficacy and safety of anifrolumab (AFM) therapy in patients with severe and moderate systemic lupus erythematosus (SLE) in real clinical practice.Material and methods. A prospective observational study (6 months) involving 14 patients with SLE (13 women and 1 man; mean age 37.5±14 years) treated in the rheumatology department of the Research Institute – Krasnodar Regional Clinical Hospital named after Professor S.V. Ochapovsky. All patients included in the study were prescribed anifrolumab (Safnelo) 300 mg parenterally once every 4 weeks.Results. Already after 3 months, regression of skin rashes was noted in all patients according to the CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index) 10.0 [4.0; 11.0] vs 2.0 [2.0; 4.0] (p=0.013). Against the background of AFM therapy, relief of articular syndrome was noted in 90% of patients in the form of a decrease in the number of painful joints 1.5 (0.0; 10.0) vs 0.5 (0.0; 4.0) (p=0.041). Three months after the start of AFM therapy, a decrease in the SLEDAI-2K (Systemic Lupus Erythematosus Disease Activity Index 2000) activity index was registered in all patients. Its median decreased from 8.0 [6.0; 8.0] to 5.0 [4.0; 7.0] (p=0.007), and after 6 months – to 2.0 [0.0; 6.0] (p=0.005). Six months after the initiation of AFM therapy, 2 (16%) patients managed to achieve a decrease in SLEDAI-2K to 0, which corresponds to the indicators of clinical and laboratory remission of SLE. The criteria for low LLDAS (Lupus Low Disease Activity State) activity after 6 months of therapy were met by 8 (66%) out of 12 patients. Against the background of AFM therapy, positive dynamics of immunological activity was noted after 3 months – a decrease in the level of anti-dsDNA by 37%, the titer of ANF by 33%. Positive dynamics of hematological syndrome was observed against the background of AFM therapy. By the 3rd month of therapy, the proportion of patients with leukopenia less than 4×109/l decreased from 21% to 0%, with lymphopenia less than 1×109/l from 21% to 16%, with thrombocytopenia less than 100×109/l from 8% to 0%, with hemolytic anemia from 8% to 0%. According to the LupusQol questionnaire, which assesses the quality of life associated with the disease, positive dynamics were recorded on all scales 6 months after the start of AFM treatment. Addition of AFM to standard therapy allowed to reduce the dose of glucocorticosteroids by 33% after 3 months from initiation and by 50% after 6 months.Conclusions. Anifrolumab is a highly effective drug for the treatment of patients with severe and moderate systemic lupus erythematosus, has a favorable tolerability and safety profile. |
| format | Article |
| id | doaj-art-bc7531e0e0ac4862bc4cc3cab0e54931 |
| institution | Kabale University |
| issn | 1995-4484 1995-4492 |
| language | Russian |
| publishDate | 2025-03-01 |
| publisher | IMA PRESS LLC |
| record_format | Article |
| series | Научно-практическая ревматология |
| spelling | doaj-art-bc7531e0e0ac4862bc4cc3cab0e549312025-08-20T03:59:31ZrusIMA PRESS LLCНаучно-практическая ревматология1995-44841995-44922025-03-01631646910.47360/1995-4484-2025-64-693045Experience of using Anifrolumab in the treatment of patients with systemic lupus erythematosusE. V. Bolotova0E. V. Jakovleva1E. K. Ilinykh2Т. A. Rassovskaya3Kuban State Medical UniversityResearch Institute – Krasnodar Regional Clinical Hospital named after Professor S.V. OchapovskyResearch Institute – Krasnodar Regional Clinical Hospital named after Professor S.V. OchapovskyResearch Institute – Krasnodar Regional Clinical Hospital named after Professor S.V. OchapovskyThe aim – evaluation of the efficacy and safety of anifrolumab (AFM) therapy in patients with severe and moderate systemic lupus erythematosus (SLE) in real clinical practice.Material and methods. A prospective observational study (6 months) involving 14 patients with SLE (13 women and 1 man; mean age 37.5±14 years) treated in the rheumatology department of the Research Institute – Krasnodar Regional Clinical Hospital named after Professor S.V. Ochapovsky. All patients included in the study were prescribed anifrolumab (Safnelo) 300 mg parenterally once every 4 weeks.Results. Already after 3 months, regression of skin rashes was noted in all patients according to the CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index) 10.0 [4.0; 11.0] vs 2.0 [2.0; 4.0] (p=0.013). Against the background of AFM therapy, relief of articular syndrome was noted in 90% of patients in the form of a decrease in the number of painful joints 1.5 (0.0; 10.0) vs 0.5 (0.0; 4.0) (p=0.041). Three months after the start of AFM therapy, a decrease in the SLEDAI-2K (Systemic Lupus Erythematosus Disease Activity Index 2000) activity index was registered in all patients. Its median decreased from 8.0 [6.0; 8.0] to 5.0 [4.0; 7.0] (p=0.007), and after 6 months – to 2.0 [0.0; 6.0] (p=0.005). Six months after the initiation of AFM therapy, 2 (16%) patients managed to achieve a decrease in SLEDAI-2K to 0, which corresponds to the indicators of clinical and laboratory remission of SLE. The criteria for low LLDAS (Lupus Low Disease Activity State) activity after 6 months of therapy were met by 8 (66%) out of 12 patients. Against the background of AFM therapy, positive dynamics of immunological activity was noted after 3 months – a decrease in the level of anti-dsDNA by 37%, the titer of ANF by 33%. Positive dynamics of hematological syndrome was observed against the background of AFM therapy. By the 3rd month of therapy, the proportion of patients with leukopenia less than 4×109/l decreased from 21% to 0%, with lymphopenia less than 1×109/l from 21% to 16%, with thrombocytopenia less than 100×109/l from 8% to 0%, with hemolytic anemia from 8% to 0%. According to the LupusQol questionnaire, which assesses the quality of life associated with the disease, positive dynamics were recorded on all scales 6 months after the start of AFM treatment. Addition of AFM to standard therapy allowed to reduce the dose of glucocorticosteroids by 33% after 3 months from initiation and by 50% after 6 months.Conclusions. Anifrolumab is a highly effective drug for the treatment of patients with severe and moderate systemic lupus erythematosus, has a favorable tolerability and safety profile.https://rsp.mediar-press.net/rsp/article/view/3698systemic lupus erythematosusanifrolumab (safnelo)interferon receptor type i inhibitorgenetically engineered biological drug |
| spellingShingle | E. V. Bolotova E. V. Jakovleva E. K. Ilinykh Т. A. Rassovskaya Experience of using Anifrolumab in the treatment of patients with systemic lupus erythematosus Научно-практическая ревматология systemic lupus erythematosus anifrolumab (safnelo) interferon receptor type i inhibitor genetically engineered biological drug |
| title | Experience of using Anifrolumab in the treatment of patients with systemic lupus erythematosus |
| title_full | Experience of using Anifrolumab in the treatment of patients with systemic lupus erythematosus |
| title_fullStr | Experience of using Anifrolumab in the treatment of patients with systemic lupus erythematosus |
| title_full_unstemmed | Experience of using Anifrolumab in the treatment of patients with systemic lupus erythematosus |
| title_short | Experience of using Anifrolumab in the treatment of patients with systemic lupus erythematosus |
| title_sort | experience of using anifrolumab in the treatment of patients with systemic lupus erythematosus |
| topic | systemic lupus erythematosus anifrolumab (safnelo) interferon receptor type i inhibitor genetically engineered biological drug |
| url | https://rsp.mediar-press.net/rsp/article/view/3698 |
| work_keys_str_mv | AT evbolotova experienceofusinganifrolumabinthetreatmentofpatientswithsystemiclupuserythematosus AT evjakovleva experienceofusinganifrolumabinthetreatmentofpatientswithsystemiclupuserythematosus AT ekilinykh experienceofusinganifrolumabinthetreatmentofpatientswithsystemiclupuserythematosus AT tarassovskaya experienceofusinganifrolumabinthetreatmentofpatientswithsystemiclupuserythematosus |